EVFM · Evofem Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $20.18M | $19.36M | $18.22M | $16.84M | $8.24M | $446.0K |
| Cost of Revenue | $4.62M | $3.83M | $6.51M | $4.42M | $4.05M | $468.0K |
| Gross Profit | $15.57M | $15.53M | $11.71M | $12.42M | $4.19M | ($22.0K) |
| R&D | - | $1.84M | $2.94M | $25.03M | $33.13M | $17.05M |
| SG&A | $7.39M | $11.56M | $14.95M | $27.56M | $24.71M | $30.09M |
| Total Operating Expenses | $16.81M | $27.04M | $36.06M | $100.96M | $104.07M | $104.07M |
| D&A | $19.0K | $30.0K | $477.0K | $1.01M | $1.02M | $302.0K |
| Operating Income | $3.37M | ($7.68M) | ($17.85M) | ($84.12M) | ($166.80M) | ($103.62M) |
| Interest Expense | $2.37M | $2.24M | $2.27M | $2.18M | $2.67M | $2.06M |
| Income Tax | $2.0K | - | $17.0K | $44.0K | $17.0K | $4.0K |
| Net Income | $391.0K | ($8.86M) | $52.98M | ($76.70M) | ($205.19M) | ($142.31M) |
| EPS - Basic | $0.00 | ($0.12) | $10.36 | ($167.50) | ($3975.00) | - |
| EPS - Diluted | $0.00 | ($0.12) | $0.05 | ($167.50) | ($3975.00) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $741.0K | $741.0K | $580.0K | $2.77M | $7.73M | $48.89M |
| Accounts Receivable | $12.48M | $9.83M | $5.74M | $1.13M | $6.45M | $1.07M |
| Inventory | $1.13M | $1.58M | $1.70M | $5.38M | $7.67M | $7.16M |
| Accounts Payable | $13.15M | $16.17M | $17.02M | $14.98M | $10.32M | $10.64M |
| Current Assets | $15.28M | $13.61M | $9.21M | $12.70M | $30.14M | $97.73M |
| Total Assets | $20.27M | $23.79M | $10.55M | $25.16M | $42.51M | $109.97M |
| Current Liabilities | $84.82M | $80.45M | $72.46M | $93.83M | $137.66M | $77.28M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $89.71M | $90.26M | $72.47M | $96.96M | $142.09M | $108.62M |
| Stockholders' Equity | ($74.34M) | ($71.26M) | ($66.51M) | ($71.80M) | ($104.31M) | $1.35M |
| Retained Earnings | ($897.39M) | ($897.66M) | ($888.70M) | ($938.69M) | ($860.68M) | ($655.49M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.99M) | ($3.88M) | ($8.97M) | ($70.41M) | ($146.67M) | ($104.83M) |
| Investing Cash Flow | ($62.0K) | ($569.0K) | ($4.0K) | ($341.0K) | ($2.69M) | $6.23M |
| Financing Cash Flow | $1.89M | $4.62M | $4.78M | $61.94M | $90.69M | $154.23M |
| CapEx | $5.0K | $14.0K | $4.0K | $341.0K | $2.94M | $2.25M |
| Free Cash Flow | ($2.00M) | ($3.90M) | ($8.97M) | ($70.75M) | ($149.61M) | ($107.08M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 77.1% | 80.2% | 64.3% | 73.8% | 50.8% | -4.9% |
| Operating margin | 16.7% | -39.6% | -98.0% | -499.6% | -2023.3% | -23234.1% |
| EBITDA margin | 16.8% | -39.5% | -95.3% | -493.6% | -2010.9% | -23166.4% |
| Net margin | 1.9% | -45.8% | 290.8% | -455.5% | -2489.0% | -31907.8% |
| Free cash flow margin | -9.9% | -20.1% | -49.2% | -420.2% | -1814.7% | -24009.6% |
| FCF / Net income | -5.11 | 0.44 | -0.17 | 0.92 | 0.73 | 0.75 |
| R&D / Revenue | - | 9.5% | 16.1% | 148.7% | 401.9% | 3822.9% |
| SG&A / Revenue | 36.6% | 59.7% | 82.1% | 163.7% | 299.7% | 6745.5% |
| Effective tax rate | 0.5% | - | 0.0% | - | - | - |
| Return on assets | 1.9% | -37.2% | 502.0% | -304.8% | -482.7% | -129.4% |
| Return on equity | -0.5% | 12.4% | -79.7% | 106.8% | 196.7% | -10564.9% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.18 | 0.17 | 0.13 | 0.14 | 0.22 | 1.26 |
| Quick ratio | 0.17 | 0.15 | 0.10 | 0.08 | 0.16 | 1.17 |
| Cash ratio | 0.01 | 0.01 | 0.01 | 0.03 | 0.06 | 0.63 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 1.4x | -3.4x | -7.9x | -38.7x | -62.6x | -50.3x |
| Equity multiplier | -0.27 | -0.33 | -0.16 | -0.35 | -0.41 | 81.64 |
| Liabilities / Assets | 4.42 | 3.79 | 6.87 | 3.85 | 3.34 | 0.99 |
| Efficiency | ||||||
| Asset turnover | 1.00 | 0.81 | 1.73 | 0.67 | 0.19 | 0.00 |
| Inventory turnover | 4.09 | 2.43 | 3.84 | 0.82 | 0.53 | 0.07 |
| Days sales outstanding | 226d | 185d | 115d | 24d | 286d | 873d |
| Days inventory outstanding | 89d | 150d | 95d | 445d | 691d | 5586d |
| Days payable outstanding | 1040d | 1540d | 954d | 1239d | 929d | 8299d |
| Cash conversion cycle | -725d | -1204d | -744d | -770d | 48d | -1840d |
| Valuation | ||||||
| P / E | - | - | 1.3x | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | 3.2x | 0.0x | 3.5x | 27.7x | 5743.1x | - |
| EV / EBITDA | 18.7x | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 4.2% | 6.3% | 8.2% | 104.2% | 1748.4% | - |
| Revenue CAGR (3y) | 6.2% | 32.9% | 244.4% | - | - | - |
| Revenue CAGR (5y) | 114.4% | - | - | - | - | - |
| Gross profit growth (YoY) | 0.2% | 32.7% | -5.8% | 196.5% | - | - |
| Operating income growth (YoY) | - | 57.0% | 78.8% | 49.6% | -61.0% | -96.5% |
| Net income growth (YoY) | - | - | - | 62.6% | -44.2% | -77.8% |
| EPS growth (YoY) | - | - | - | 95.8% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 48.8% | 56.5% | 87.3% | 52.7% | -39.7% | -89.0% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -4.3% | -7.1% | 7.4% | 31.2% | - | -91.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$18.20M totalPhexxi$18.20M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-38.79
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✓Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Evofem Biosciences against the 5 most active filers in the same SIC group.